A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy

• Published in: Journal of allergy and clinical immunology Vol. 137; no. 4; pp. 1103 - 1110.e11
• Main Authors: Wood, Robert A., Kim, Jennifer S., Lindblad, Robert, Nadeau, Kari, Henning, Alice K., Dawson, Peter, Plaut, Marshall, Sampson, Hugh A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2016; Elsevier Limited
• Subjects: Administration, Oral; Adolescent; Adult; Allergy and Immunology; Anti-Allergic Agents - therapeutic use; Asthma; Child; Combined Modality Therapy; desensitization; Desensitization, Immunologic - methods; dose-related adverse reactions; double-blind; Double-Blind Method; Drug Administration Schedule; FDA approval; Female; Food; Food allergies; Humans; Immunotherapy; Logistic Models; Male; Milk; Milk allergy; Milk Hypersensitivity - therapy; omalizumab; Omalizumab - therapeutic use; oral immunotherapy; placebo-controlled trial; Proteins; sustained unresponsiveness; Treatment Outcome; Young Adult; SU; dose-related adverse reactions; MOIT; oral immunotherapy; OFC; desensitization; placebo-controlled trial; APC; SCD; CMA; SPT; sustained unresponsiveness; Milk allergy; omalizumab; OIT; double-blind; Oral food challenge; Skin prick test; Successfully consumed dose; Cow's milk allergy; Milk oral immunotherapy; Antigen-presenting cell

Although studies of oral immunotherapy (OIT) for food allergy have shown promise, treatment is frequently complicated by adverse reactions and, even when successful, has limited long-term efficacy because benefits usually diminish when treatment is discontinued. We sought to examine whether the addi...